Afya (AFYA) Q2 2024: Margin Expands 490bps as Segment Restructuring Drives Profitability
Afya delivered a step-change in profitability this quarter, with margin expansion underpinned by operational restructuring and segment integration. The company’s core medical education business continues to anchor growth, while recent M&A and digital solution streamlining are translating into tangible cost and revenue synergies. Revised guidance signals management’s confidence in sustainable margin gains and robust cash generation into the second half.
Summary
- Segment Integration Unlocks Margin: Restructuring and recent acquisitions are driving meaningful efficiency improvements.
- Medical Education Remains Core Engine: Undergrad and continuing education segments outperform, supporting guidance raise.
- Guidance Upgrade Anchored in Execution: Management signals confidence in sustained profitability and cash flow trajectory.
Business Overview
Afya is a leading Brazilian education platform focused on medical and health sciences education, generating revenue through undergraduate medical programs, continuing education, and digital medical practice solutions. The business is organized into three segments: undergrad programs (core medical school and health degrees), continuing education (graduate, prep, and residency journeys), and medical practice solutions (digital tools and B2B services for healthcare professionals and pharmaceutical partners).
Performance Analysis
Afya posted double-digit top-line growth as net revenue advanced nearly 14% year-over-year, propelled by a combination of higher medical seat approvals, ticket price increases, and the integration of recent acquisitions. The undergrad segment remains the lion’s share of the business, with 86% of undergrad revenue tied to medicine and 94% to health-related courses, underscoring the company’s defensible niche.
Profitability inflected sharply, with adjusted EBITDA margin expanding 490 basis points to 42.5% in Q2, a direct result of segment restructuring, operational leverage, and disciplined SG&A management. Cash flow from operations climbed 21% year-over-year, with robust 94% cash conversion, supporting a net debt reduction and a strong liquidity position. EPS growth outpaced revenue, reflecting both margin gains and lower financial expense as net debt and interest costs declined.
- Medical Seat Expansion: Approved seats rose to 3,583 post-quarter, supporting future intake and revenue visibility.
- Continuing Education Growth: Segment net revenue climbed 12% year-over-year, with B2B softness offset by strong B2C intake.
- Medical Practice Solutions Recovery: Revenue rebounded 13% as B2B invoice timing normalized and active payer base grew double digits.
Operational and financial outperformance across all segments underpinned management’s decision to revise full-year guidance upward, reflecting both organic execution and M&A contributions.
Executive Commentary
"Our medical educational business remains and will continue to be the foundations of our business in the short and middle term, driving consistent growth alongside strong profitability and cash generation."
Vigilio Gibon, CEO
"The adjusted dividend margin expansion is mainly due to gross margin expansions within undergrad and continuing education, completion of UNIMA and FCM, Jaboatão integration process in November, 2023. The ramp-up of the Four Mais Médicos campus that started operations in third quarter of 2022, operation restructuring efforts in our continual educational and medical practice solution segments, and more efficient in selling general and administrative expenses."
Luiz André Blanca, CFO
Strategic Positioning
1. Segment Realignment and Operational Restructuring
Afya’s major segment restructuring—including the reclassification of digital services as medical practice solutions and the migration of content/technology offerings into continuing education—has streamlined operations. This move enables shared product and tech teams and reduces duplication, driving both cost savings and faster product iteration.
2. M&A Integration and Scale Synergies
Recent acquisitions, notably Unidom and UNIMA, are already delivering integration benefits. Management highlighted leaner cost structures, curriculum standardization, and centralized back office as key levers to unlock margin and revenue synergies. The pipeline for further M&A remains robust, with management disciplined on price and region selection.
3. Core Medical Education Resilience and Expansion
Medical school remains Afya’s cash engine, with approved seat expansion and ticket price increases supporting long-term growth. The intake cycle remains robust, and regulatory approvals for additional seats continue, albeit at a measured pace. This entrenched position in a capacity-constrained market is a core competitive advantage.
4. Digital and B2B Solutions Diversification
The medical practice solutions segment is recovering, driven by B2B marketing campaigns for pharmaceutical clients and a growing active payer base. While B2B in continuing education is now deprioritized, digital solutions are positioned for margin improvement, with contribution margin targeted in the mid-teens to 20% range as restructuring benefits flow through.
5. Financial Discipline and Capital Structure Optimization
Net debt reduction and the new IFC sustainability-linked loan (up to R$500M) provide financial flexibility for continued M&A and operational investment, with cost of debt expected to remain below the Brazilian CDI rate through 2026.
Key Considerations
This quarter marks a turning point for Afya’s margin profile, operational focus, and capital allocation discipline. The following considerations will shape the investment case into the second half and beyond:
- Margin Expansion Sustainability: Can Afya maintain its improved EBITDA margin as new campuses and segments scale, or will integration costs and competitive wage pressure resurface?
- Regulatory Capacity Approvals: The pace and volume of new seat approvals from Brazil’s Ministry of Education remain a gating factor for long-term growth.
- B2B and Digital Revenue Mix: The rebound in medical practice solutions is encouraging, but B2B in continuing education is now structurally less relevant, requiring continued focus on B2C and value-added digital offerings.
- M&A Pipeline Execution: Management’s disciplined approach to acquisitions will be tested as more institutions come to market following regulatory shifts.
Risks
Regulatory unpredictability remains a fundamental risk, as the pace of seat approvals and the outcome of Supreme Court injunctions could materially impact growth. Competitive intensity in prep courses and digital services may pressure pricing and enrollment, particularly in peak sales quarters. Integration execution for recent and future acquisitions is critical to realizing planned synergies and avoiding margin dilution. Finally, any reversal in Brazil’s macro environment or education funding could challenge both demand and debt servicing.
Forward Outlook
For Q3 2024, Afya guided to:
- Net revenue in the R$3.225B to R$3.325B range
- Adjusted EBITDA between R$1.375B and R$1.475B
- Capex of R$220M to R$260M
For full-year 2024, management raised guidance to reflect outperformance in all three segments, robust intake, and the integration of Unidom and new seat approvals:
- Stronger enrollment and margin performance in undergrad and continuing education
- Medical practice solutions expected to deliver double-digit growth and positive EBITDA margin near 20%
Management highlighted that synergy capture from M&A, ongoing operational improvements, and disciplined SG&A control are key drivers of the upgraded outlook.
Takeaways
Afya’s Q2 results confirm a structural margin reset and validate the company’s shift to a more integrated, scalable model.
- Margin Inflection: Restructuring and integration are driving margin expansion well ahead of prior years, with cash flow and net income leverage following suit.
- Segment Strength: Core medical education and continuing education outperformed, while digital and B2B solutions are recovering and now contributing to profitability.
- Watch Regulatory and M&A Execution: The sustainability of growth and margin gains will hinge on regulatory seat approvals and disciplined integration of new acquisitions.
Conclusion
Afya’s second quarter demonstrates that operational discipline, segment integration, and a focus on core medical education can unlock both top-line growth and margin expansion. The company’s raised guidance and strong cash flow provide confidence, but execution on M&A and regulatory navigation remain key forward levers for investors to monitor.
Industry Read-Through
Afya’s results offer a strong signal for the broader Brazilian education sector: Structural margin gains are achievable through segment consolidation, digital product rationalization, and disciplined M&A. The medical education niche, with its regulatory barriers and capacity constraints, continues to offer defensible growth and pricing power relative to generalist education peers. However, the importance of regulatory risk and integration discipline is underscored—players unable to navigate these forces may face margin compression or stalled growth. For digital health and B2B education providers, Afya’s shift toward integrated product teams and value-added digital services sets a template for operational leverage and profitability improvement.